JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Prognostic importance of PET score obtained from IMPeTUs criteria in multiple myeloma
Abstract
Aims: Multiple myeloma (MM) is a clonal plasma cell malignancy that infiltrates the bone marrow, bone, and sometimes extramedullary sites. Reliable staging and prognostic factors are essential for patient management. Imaging modalities, especially 18F-FDG PET/CT, are essential for the assessment of disease extent. This study evaluates a scoring system based on the IMPeTUs criteria for predicting progression-free survival (PFS) in MM.
Methods: This study included 35 newly diagnosed, treatment-naive MM patients (13 females, 22 males). Baseline 18F-FDG PET/CT scans were obtained within one month of diagnosis. Five different assessments were performed. The PET score is a scoring system adapted from the previously established IMPeTUs to provide a more nuanced assessment of PET scan results in newly diagnosed patients. This system incorporates the DS (Deauville score), a standardised measure of treatment response in lymphoma, together with an assessment of the number of lesions seen on the PET scan.
Results: The mean age of the cohort was 65 years. Ig G kappa was the most common MM type (37.1%). Diffuse bone marrow uptake and focal lesions were observed in 37.2% and 57.2% of patients, respectively, DS ?4. The PET score cut-off of 6.5 predicted PFS with 61.5% sensitivity and 72.7% specificity (AUC 0.715). Median PFS was significantly different between patients with PET score <6.5 and ?6.5 (35±4.1 months vs. 23.6±4.03 months, p=0.027).
Conclusion: The PET score cut-off value of 6.5 serves as a potential prognostic tool for MM, aiding in patient stratification and treatment decisions.

Keywords : Multiple myeloma, positron-emission tomography, neoplasm staging

Download Article


1. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am. 1999;13(6):1295-xi. doi:10.1016/s0889-8588(05)70128-3
2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-2869. doi:10.1200/JCO. 2015.61.2267
3. Cavo M, Terpos E, Nanni C, et al. Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18(4):e206-e217. doi:10.1016/S1470-2045(17) 30189-4
4. Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: how? When? Blood. 2019;133(7):644-651. doi:10.1182/blood-2018-08-825356
5. Zamagni E, Tacchetti P, Barbato S, Cavo M. Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients. J Clin Med. 2020;9(11):3519. doi:10.3390/jcm9113519
6. Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020;99(1):127-135. doi:10.1007/s00277-019-03852-2
7. Marchiori S, Cousin F, Papadopoulos I, et al. Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [<sup>18</sup>F]FDG PET/CT in patients with newly diagnosed multiple myeloma. EJNMMI Res. 2024;14:51.
8. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-5995. doi:10.1182/blood-2011-06-361386
9. Nanni C, Zamagni E, Versari A, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43(3):414-421. doi:10.1007/s00259-015-3200-9
10. Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET use). Eur J Nucl Med Mol Imaging. 2018;45(5):712-719. doi:10.1007/s00259-017-3909-8
11. Nanni C. PET-FDG: impetus. Cancers (Basel). 2020;12(4):1030. doi:10. 3390/cancers12041030
12. Nanni C, Cottereau AS, Lopci E, et al. Report of the 6<sup>th</sup> International workshop on PET in lymphoma. Leuk Lymphoma. 2017;58(10):2298-2303. doi:10.1080/10428194.2017.1298752
13. Zukovs R, Antke C, Mamlins E, et al. <sup>18</sup>F-FDG-PET/CT in relapsed multiple myeloma: are prognostic thresholds different from first-line therapy? BMC Med Imaging. 2022;22(1):63. doi:10.1186/s12880-022-00788-4
14. Deng S, Zhang B, Zhou Y, et al. The role of <sup>18</sup>F-FDG PET/CT in multiple myeloma staging according to impetus: comparison of the durie-salmon plus and other staging systems. Contrast Media Mol Imaging. 2018;2018: 4198673. doi:10.1155/2018/4198673
15. Sachpekidis C, Enqvist O, Ul&eacute;n J, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [<sup>18</sup>F]FDG PET/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024;51(8):2293-2307. </ol> </div> <p>
Article available in :
Volume 8, Issue 3, 2025
Page : 430-434
https://doi.org/10.32322/jhsm.1655956
Article Information
Received : 11 Mar 2025
Accepted : 21 Nis 2025
Published : 30 May 2025
Corresponding Author :

Özlem Beyler: Department of Hematology, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkiye

[email protected]
Citation : Beyler Ö, Kaplan İ, Demir C, Can C, Kömek H. Prognostic importance of PET score obtained from IMPeTUs criteria in multiple myeloma. J Health Sci Med. 2025;8(3):430-434.

Read: 9
Cited: 0
Download : 9
_Footer